ELOX // Eloxx Pharmaceuticals Inc.

DES <GO> NASDAQ RQD COCKPIT → CIK 0001035354 ↗

Health Care • Biotechnology: Biological Products (No Diagnostic Substances)

$13.45 ▲ +0.25 (+1.89%)

MKT CAP: $54.3M • VOL: 14.0K

52W L $8 52W H $23

PIOTROSKI

1 / 9

ELOX // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE

▼ DOWNGRADE // D- (RQD 42) -> E (RQD 32) AS OF 2026-11-03

ROARABLE E

RQD CONFIDENCE

32 / 100 -10D

5 X 20-PT QUANT PILLARS

E 0 D 35 C 59 B 70 A 86+

Roarable Strong Sell — Forensic Risk / Avoid

01 MASSIVE / SEC XBRL

Forensic Fundamentals

6 / 20

CRITICAL

FCF -34.2% vs NI -90.7% • ROIC-WACC -43.6% • Z 3.2

02 INSTITUTIONAL TAPE & TREND

Whale & Options Flow

6 / 20

CRITICAL

52W RANGE 35% • VS 200D -8.4% • RSI 45.4

03 SEC XBRL CAPITAL ALLOCATION

Insider & Capital Conviction

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

04 FRED 90D r-MATRIX

Macro Regime Fit

7 / 20

WARNING

HEADWIND • r(10Y)=-0.04 (+19bp) • r(OAS)=-0.08

05 10-K REDLINE AUDIT

Forensic 10-K Risk

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

ALERT

Why did ELOX's Insider & Capital Conviction & Forensic 10-K Risk sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever ELOX is Upgraded or Downgraded.

SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON ELOX)

STAGE 2 DETERMINISTIC Z-SCORE + STAGE 3 GEEK DESK BRIEF ALL MARKET ANOMALIES <SIG>

▲ BULLISH // MACRO TAILWIND SCORE (96/100)SIFTER 05 // TRUE NET LIQUIDITY BETA

SEVERITY: 94/100 Z-SCORE: +6.01σ

ELOX Liquidity Tailwind Hits 96/100 Despite Net Liquidity Slipping -0.64% to $5,746B

TRUE NET LIQUIDITY

$5,746B (-0.64% 4W)

NET LIQUIDITY ELASTICITY

6.00x BETA (r=-0.42)

MACRO TAILWIND SCORE

96 / 100

[GEEK DESK FORENSIC NOTE // FRED WALCL - TGA - RRP × 5Y BETA]

FRED Fed Assets (WALCL)US Treasury TGA (WTREGEN) + ON RRPICE BofA High-Yield OAS + 5Y Equity Beta

Multi-feed macro modeling registers a 6.01 z-score liquidity tailwind anomaly for Eloxx Pharmaceuticals with a Macro Tailwind Score of 96 / 100. True Net Liquidity contracted -0.64% over the 4-week window to $5,746B while ICE BofA High-Yield OAS widened by 34 bps. However, an extreme Net Liquidity Elasticity of 6.00x beta alongside a pearson R of -0.42 establishes an outsized sensitivity profile for institutional positioning.

ELOX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.16%📐 HORIZONTAL RANGE

2026-11-03O $13.20H $13.45L $13.20C $13.45VOL 14.0K

RES: $29.68SUP: $11.26SMA50: $15.19SMA200: $14.68

ELOX // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE

UNDERWEIGHT CONVICTION: 28/100

BEAR 0

100 BULL

Eloxx Pharmaceuticals Inc. (ELOX) exhibits 45.0% gross margins and -35.0% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)

01. Operating Leverage & Capital Efficiency Moat

Sustained 45.0% gross profitability converts into — operating margin and -35.0% ROIC, outpacing sector cost of capital.

ROIC: -35.0% // GM: 45.0%

02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of — paired with -11.87% free cash flow yield supports self-funded R&D and capital return.

REV YOY: — // FCF YLD: -11.87%

03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 3.80 and Piotroski F-Score of 1/9 indicate low near-term refinancing stress.

ALTMAN Z: 3.80 // F-SCORE: 1/9

▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)

01. Multiple Compression & Duration Sensitivity

Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 24.0x // EV/EBITDA: —

02. Options Skew & Event Volatility Risk

Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $13.45 max pain.

IMPL MOVE: ±5.2% // P/C: 0.85

03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend — net margins.

NET MARGIN: — // D/E: 0.45x

KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs — forward consensus, and institutional 13F positioning.

MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.10).

FORM 4 & 13F FLOW OPEN OWN <GO>

FILER	SIDE	$ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>

UNUSUAL OPTIONS TAPE OPEN OPT <GO>

STRIKE / EXP	TYPE	PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>

KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>

TRAILING P/E —

FORWARD P/E —

EV / EBITDA —

FCF YIELD -11.87%

GROSS MARGIN —

OPERATING MARGIN —

NET MARGIN —

ROIC % -35.0%

REV GROWTH YOY —

DILUTED EPS TTM —

DEBT / EQUITY —

DIVIDEND YIELD 0.00%

RSI-14 MOMENTUM 45.4

5Y EQUITY BETA —

FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>

MACRO CORRELATION CALIBRATION ACTIVE BELOW.

FRED MACRO REGIME STRESS-TEST SIMULATOR // ELOXPEARSON R VARIANCE ENGINE

01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO

02 // POSITION NOTIONAL EXPOSURE

HEADLINE STRESS SCORE

75/100SEVERE DRAWDOWN PRESSURE

PRIMARY FACTOR EXPOSURE

DFII10 // -0.61 r

Latest: 2.08%

EST. DIRECTIONAL MOVE

-8.50%

Implied Px: $12.31

EST. DOLLAR VARIANCE

-$4,248

On $50,000 Notional

[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ELOX & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>

ELOX VS LLY

MARGINS ROIC VALUATION

ELOX VS JNJ

MARGINS ROIC VALUATION

ELOX VS ABBV

MARGINS ROIC VALUATION

ELOX VS MRK

MARGINS ROIC VALUATION